1051 related articles for article (PubMed ID: 33627412)
1. Rescuing the Last-Line Polymyxins: Achievements and Challenges.
Nang SC; Azad MAK; Velkov T; Zhou QT; Li J
Pharmacol Rev; 2021 Apr; 73(2):679-728. PubMed ID: 33627412
[TBL] [Abstract][Full Text] [Related]
2. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J
Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
[TBL] [Abstract][Full Text] [Related]
3. History, Chemistry and Antibacterial Spectrum.
Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
[TBL] [Abstract][Full Text] [Related]
4. Reviving Polymyxins: Achievements, Lessons and the Road Ahead.
Li J
Adv Exp Med Biol; 2019; 1145():1-8. PubMed ID: 31364067
[TBL] [Abstract][Full Text] [Related]
5. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
Zavascki AP; Goldani LZ; Li J; Nation RL
J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
[TBL] [Abstract][Full Text] [Related]
6. Multidrug-resistant Gram-negative infections: what are the treatment options?
Giamarellou H; Poulakou G
Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
[TBL] [Abstract][Full Text] [Related]
9. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A; Izanloo A; Rastegar M
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
[TBL] [Abstract][Full Text] [Related]
10. Polymyxin antibiotics for gram-negative infections.
Arnold TM; Forrest GN; Messmer KJ
Am J Health Syst Pharm; 2007 Apr; 64(8):819-26. PubMed ID: 17420197
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
[TBL] [Abstract][Full Text] [Related]
12. Rational use of intravenous polymyxin B and colistin: A review.
Zakuan ZD; Suresh K
Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
[TBL] [Abstract][Full Text] [Related]
13. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
Falagas ME; Kasiakou SK
Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
[TBL] [Abstract][Full Text] [Related]
14. A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens.
Roberts KD; Zhu Y; Azad MAK; Han ML; Wang J; Wang L; Yu HH; Horne AS; Pinson JA; Rudd D; Voelcker NH; Patil NA; Zhao J; Jiang X; Lu J; Chen K; Lomovskaya O; Hecker SJ; Thompson PE; Nation RL; Dudley MN; Griffith DC; Velkov T; Li J
Nat Commun; 2022 Mar; 13(1):1625. PubMed ID: 35338128
[TBL] [Abstract][Full Text] [Related]
15. Multidrug-Resistant Gram-Negative Pathogens: The Urgent Need for 'Old' Polymyxins.
Paterson DL; Bonomo RA
Adv Exp Med Biol; 2019; 1145():9-13. PubMed ID: 31364068
[TBL] [Abstract][Full Text] [Related]
16. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
[TBL] [Abstract][Full Text] [Related]
17. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
[TBL] [Abstract][Full Text] [Related]
18.
Duncan LR; Wang W; Sader HS
Antimicrob Agents Chemother; 2022 May; 66(5):e0013922. PubMed ID: 35475635
[TBL] [Abstract][Full Text] [Related]
19. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.
Velkov T; Roberts KD; Nation RL; Wang J; Thompson PE; Li J
ACS Chem Biol; 2014 May; 9(5):1172-7. PubMed ID: 24601489
[TBL] [Abstract][Full Text] [Related]
20. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.
Falagas ME; Kasiakou SK; Tsiodras S; Michalopoulos A
Clin Med Res; 2006 Jun; 4(2):138-46. PubMed ID: 16809407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]